

**Interaction Report****Report ID:****Date Produced:** 27 January 2022**Antiretroviral Treatment****Co-medications**

Raltegravir (RAL)

Magnesium supplements

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org).

**Description of the interactions**

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

**Raltegravir (RAL) + Magnesium supplements**

Caution is recommended when prescribing magnesium supplements. Raltegravir binds to divalent cations such as magnesium and forms a complex at the level of the gastro-intestinal tract which results in less raltegravir being absorbed. Administration of raltegravir 400 mg twice daily should be separated by at least 4 hours. Importantly, drug-drug interaction studies with antacids containing divalent cations have shown a more pronounced reduction in raltegravir C<sub>min</sub> when raltegravir was administered once daily compared to a twice daily regimen. A similar effect for magnesium supplements cannot be excluded, therefore, twice daily administration of raltegravir should be preferred.